These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 26259878

  • 1. Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
    Francis RJ, Segard T, Morandeau L, Lee YC, Millward MJ, Segal A, Nowak AK.
    Lung Cancer; 2015 Oct; 90(1):55-60. PubMed ID: 26259878
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y, Takuwa T, Miyata Y, Fukuoka K, Hasegawa S, Nakano T, Okada M.
    Ann Oncol; 2013 Apr; 24(4):1005-10. PubMed ID: 23136224
    [Abstract] [Full Text] [Related]

  • 3. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T.
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [Abstract] [Full Text] [Related]

  • 4. Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
    Pinelli V, Roca E, Lucchini S, Laroumagne S, Loundou A, Dutau H, Maldonado F, Astoul P.
    Respiration; 2015 Jan; 89(6):558-64. PubMed ID: 25966972
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 7. 18F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center.
    Elliott HS, Metser U, de Perrot M, Cho J, Bradbury P, Veit-Haibach P, Hussey D, Noam T.
    Br J Radiol; 2018 Jun 20; 91(1086):20170814. PubMed ID: 29498536
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma.
    Ozmen O, Koyuncu A, Koksal D, Tatci E, Alagoz E, Demirag F, Gokcek A, Arslan N.
    Nucl Med Commun; 2016 Jan 20; 37(1):43-9. PubMed ID: 26440572
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.
    Lim JH, Choi JY, Im Y, Yoo H, Jhun BW, Jeong BH, Park HY, Lee K, Kim H, Kwon OJ, Han J, Ahn MJ, Kim J, Um SW.
    PLoS One; 2020 Jan 20; 15(2):e0229299. PubMed ID: 32069313
    [Abstract] [Full Text] [Related]

  • 12. Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.
    Segard T, Robins PD, Yusoff IF, Ee H, Morandeau L, Campbell EM, Francis RJ.
    Clin Nucl Med; 2013 Jan 20; 38(1):1-6. PubMed ID: 23242037
    [Abstract] [Full Text] [Related]

  • 13. Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI.
    Murphy DJ, Mak SM, Mallia A, Jeljeli S, Stirling JJ, Goh V, Bille A, Cook GJR.
    Eur J Radiol; 2019 Jun 20; 115():46-52. PubMed ID: 31084758
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
    Genestreti G, Moretti A, Piciucchi S, Tiseo M, Bersanelli M, Scarlattei M, Scarpi E, Dubini A, Matteucci F, Sanna S.
    Technol Cancer Res Treat; 2012 Apr 20; 11(2):163-7. PubMed ID: 22335410
    [Abstract] [Full Text] [Related]

  • 15. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
    Mavi A, Basu S, Cermik TF, Urhan M, Bathaii M, Thiruvenkatasamy D, Houseni M, Dadparvar S, Alavi A.
    Mol Imaging Biol; 2009 Apr 20; 11(5):369-78. PubMed ID: 19472014
    [Abstract] [Full Text] [Related]

  • 16. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S, Shiga T, Yasuda K, Watanabe S, Hirata K, Nishijima KI, Magota K, Kasai K, Onimaru R, Tuchiya K, Kuge Y, Shirato H, Tamaki N.
    Eur J Nucl Med Mol Imaging; 2016 Nov 20; 43(12):2147-2154. PubMed ID: 27251644
    [Abstract] [Full Text] [Related]

  • 17. FDG PET/CT is useful for detecting infiltration to the port site in patients with malignant pleural mesothelioma.
    Kawaguchi K, Taniguchi T, Usami N, Fukui T, Ishiguro F, Nakamura S, Yokoi K.
    Gen Thorac Cardiovasc Surg; 2014 Mar 20; 62(3):157-62. PubMed ID: 24281913
    [Abstract] [Full Text] [Related]

  • 18. Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice.
    Colin DJ, Bejuy O, Germain S, Triponez F, Serre-Beinier V.
    J Vis Exp; 2019 Dec 21; (154):. PubMed ID: 31904012
    [Abstract] [Full Text] [Related]

  • 19. Positron emission tomography/computed tomography imaging of residual skull base chordoma before radiotherapy using fluoromisonidazole and fluorodeoxyglucose: potential consequences for dose painting.
    Mammar H, Kerrou K, Nataf V, Pontvert D, Clemenceau S, Lot G, George B, Polivka M, Mokhtari K, Ferrand R, Feuvret L, Habrand JL, Pouysségur J, Mazure N, Talbot JN.
    Int J Radiat Oncol Biol Phys; 2012 Nov 01; 84(3):681-7. PubMed ID: 22391104
    [Abstract] [Full Text] [Related]

  • 20. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
    Marin-Oyaga VA, Salavati A, Houshmand S, Pasha AK, Gharavi M, Saboury B, Basu S, Torigian DA, Alavi A.
    Hell J Nucl Med; 2015 Nov 01; 18(1):11-8. PubMed ID: 25679073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.